ArticleLeukemia2020
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.
Abstract readLetter
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Intercellular Mitochondrial Transfer as Endogenous Neuroprotection: Mechanisms and Therapeutic Implications in Ischemic Stroke.Translational stroke research · 2026Review
- TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potentHaematologica · 2026Article
- Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study.Annals of hematology · 2026Article
- Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies.Journal for immunotherapy of cancer · 2025Article
- B cell targeted CAR-T therapy for autoimmune diseases.Frontiers of medicine · 2025Review
- Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2025Review
- Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma.Blood advances · 2025Article
- Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin-6 receptor overexpression.British journal of haematology · 2025Article
- CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention.Leukemia · 2025Article
- The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse.Journal of experimental & clinical cancer research : CR · 2025Article
- Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma.Blood neoplasia · 2024Article
- Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.International journal of molecular sciences · 2024Article
- Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell linesFrontiers in immunology · 2024Article
- Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.Cancer medicine · 2023Review
- EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.Leukemia · 2023Article
- Article
- CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NADAntioxidants (Basel, Switzerland) · 2023Article
- Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.Oncoimmunology · 2023Article
- Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.Blood advances · 2022Article
- The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Priya ChoudhryDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Margarette C MarianoDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Huimin GengDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Thomas G MartinDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
Jeffrey L WolfDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
Sandy W WongDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
Nina ShahDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
Arun P WiitaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA. arun.wiita@ucsf.edu.ORCID http://orcid.org/0000-0002-7465-6964
Funding
In vivo monitoring of oxidative protein folding through time-resolved quantitative mass spectrometryDP2GM123500 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2016 to 2016
$1.9MExploiting myeloma proteome remodeling to extend proteasome inhibitor efficacyR01CA226851 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2018 to 2022
$1.6MGlobal Assessment of Myeloma Response to ChemotherapyK08CA184116 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2014 to 2018
$684kNCI NIH HHS K08 CA184116NCI NIH HHS R01 CA226851NIGMS NIH HHS DP2 GM123500
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Expression Regulation, NeoplasticADP-ribosyl Cyclase 1Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDNA (Cytosine-5-)-Methyltransferase 1Drug Screening Assays, AntitumorDrug SynergismHumansMultiple MyelomaPlasma CellsADP-ribosyl Cyclase 1Antibodies, MonoclonaldaratumumabDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.